Financials data is unavailable for this security.
View more
Year on year EyePoint Pharmaceuticals Inc grew revenues 11.14% from 41.40m to 46.02m while net income improved from a loss of 102.25m to a smaller loss of 70.80m.
Gross margin | 91.35% |
---|---|
Net profit margin | -172.29% |
Operating margin | -195.71% |
Return on assets | -34.74% |
---|---|
Return on equity | -60.81% |
Return on investment | -47.07% |
More ▼
Cash flow in USDView more
In 2023, EyePoint Pharmaceuticals Inc increased its cash reserves by 193.80%, or 185.63m. Cash Flow from Financing totalled 187.07m or 406.51% of revenues. In addition the company generated 1.88m in cash from operations while cash used for investing totalled 3.32m.
Cash flow per share | -1.84 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 4.38 |
---|---|
Tangible book value per share | 4.38 |
More ▼
Balance sheet in USDView more
Current ratio | 4.75 |
---|---|
Quick ratio | 4.69 |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼